Pay in 4 interest-free payments of $5.57 Learn more
Ships within 48 hours · Estimated delivery Aug 19 - Aug 24
Research evaluating whether the GLP-1 receptor agonist semaglutide is superior to placebo in reducing body weight and knee osteoarthritis pain is summarized in a new Quick Take video
95% CI 0.501.20, I2 0%) (Fig
Supports metabolic balance alongside diet and activity
GLP-1 receptor agonists such as semaglutide and tirzepatide-related therapies have strong evidence for diabetes and weight management when used appropriately
It is FDA-approved and classified as a controlled substance, and it is intended for short-term use
It is primarily involved in the transport of long-chain fatty acids into the mitochondria, where they are burned for energy
US$ 22.88
US$ 23.10
US$ 26.03
US$ 21.78
US$ 29.50
